C06再生醫療(細胞治療、基因治療、組織工程等)

Exopharm is a clincial-stage Australian biotechnology company using exosomes (extracellular vesicles (EVs)) from cells to generate a new class of transformative medicines. The company’s proprietary EV engineering technologies enable improved loading of nucleic acid medicines into EVs, and allow EVs to be directed towards selected cell types. Together with its LEAP technology, which allows large-scale and economical isolation of exosomes, Exopharm is using combinations of its engneering technologies to develop a pipeline of EEV products for a range of clinical applications, including neurological diseases, infectious diseases, cancer and fibrosis.